Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
2,985 total articles
Verastem is trading at $5.82 with tangible clinical readouts and regulatory milestones looming into the first half of 2026. The balance sheet and enterprise value leave room for partner-led upside; we maintain Buy with a long-term trade plan to capture data-driven revaluation while limiting downside with a tight stop.
Copa Holdings (CPA) looks like a structurally profitable regional airline that has been punished in the short term. With a market cap near $4.56B, a P/E around 6.8, and a dividend yield close to 5.93%, the stock offers asymmetric upside if traffic and margins remain healthy. This trade idea lays out a clear entry at $111.00, a stop at $95.00 and a …
Brookfield Asset Management is seeing assets under management climb alongside a steady free cash flow profile and low leverage. The setup offers a mid-term opportunity to capture mean reversion toward prior valuation levels, with entry at $43.50, a stop at $40.00 and a $52.00 target over the next 45 trading days.
FactSet (FDS) is being punished in the market as investors extrapolate AI-driven disintermediation across financial services. That narrative discounts FactSet's subscription durability, 27.7% ROE, $647M in free cash flow and a sub-13x P/E. We recommend a tactical long for a mid-term rebound: enter at $207.49, stop $190.00, target $260.00 (45 tradin…
Alibaba reported a mixed quarter on 03/19/2026: revenue growth slowed to +2% while adjusted EBITA plunged 57%, but cloud intelligence revenue and AI product traction remain strong. The stock is trading oversold with a 14-day RSI ~26 and a market cap near $302B. I think this is a worthwhile long trade on weakness with defined entry, stop and a 180-t…
A pullback in private credit is reducing the ability of smaller chip startups and captive AI silicon projects to scale. That dynamic benefits incumbents that combine design scale, foundry relationships, and clean balance sheets. Advanced Micro Devices (AMD) checks those boxes: $6.7B free cash flow, near-zero leverage, and a market cap of roughly $3…
Abeona (ABEO) is a small-cap gene-therapy developer that now has an FDA-approved, autologous cell-based therapy - ZEVASKYN - for RDEB. With approval in hand and early payer coverage, the stock offers a high-risk, high-reward trade: entry at $4.53, stop at $3.70, target $8.00 over a 180 trading-day horizon.
Ichor reported an earnings beat and issued optimistic 2026 quarterly guidance, signaling margin recovery and sequential revenue growth. With a $1.68B market cap, improving short interest dynamics and low leverage, the stock has room to run. This trade idea outlines an actionable mid-term long with entry, stop and target levels and balanced risk con…
L'Oreal's recent share buyback, steady 2025 sales of €44.05 billion and a technically oversold ADR (RSI ~31) create a compelling setup for long-term investors. I upgrade the name to attractive for a long-term trade with a clear entry at $79.90, a stop at $70.00 and a target of $95.00 over the next 180 trading days.
Titan Machinery is trading cheaply relative to sales and book with strong free cash flow and an improving European franchise. Expect short-term pressure from margin compression and inventory rationalization, but the balance sheet and cash generation justify a tactical long for patient traders.
FMC is trading near its 52-week low after a brutal 2025. Management is exploring strategic alternatives, which creates a clear binary: a sale or renewed execution. This trade idea buys the rumor with a strict stop and a mid-term horizon to capture a potential takeover premium or short-covering rally while acknowledging the company’s negative earnin…
Twilio’s communications platform is showing durable adoption amid AI-driven product upgrades and improving expansion metrics. The company generates nearly $1.0B in free cash flow, carries modest leverage, and trades at a reasonable price-to-sales multiple for a growth software name. This idea buys a controlled pullback with a clear stop and a targe…
Adobe shares have sold off hard into 2026 on headlines - CEO transition, a $150M DOJ settlement and AI disruption fears - but fundamentals remain robust: ~$101B market cap, P/E ~14, free cash flow near $9.85B, and explicit AI partnerships that can re-accelerate revenue per seat. This trade idea takes a long stance over a 45-trading-day swing while …
Geron reported $184M of RYTELO revenue in 2025 and guided to $220-240M for 2026. The company carries roughly $400M in cash and has cut costs, yet valuation already prices slim growth. High short interest and upcoming commercial execution milestones create a technical and fundamental inflection that could push the stock higher. This trade lays out a…
POET Technologies is moving beyond proof-of-concept. Strategic partnerships with LITEON and Lessengers, confirmed prototype timelines, and fresh capital after a registered offering put optical interposer commercialization on the table. For traders, a defined long into late-2026 catalysts offers asymmetric upside versus a clear stop for dilution and…
Credo Technology (CRDO) just reported a blowout revenue quarter and ultra-high gross margins, yet the stock has pulled back into technical support and below its moving averages. I was bearish earlier; new data and product ramps force a rethink. This is a trade idea: aggressive long entry at current levels with a medium-to-high risk posture and a lo…
Telephone and Data Systems (TDS) is a post-sale telecom with a cleaner balance sheet, significant free cash flow and an under-appreciated valuation. We outline a long trade with precise entry, stop and target, driven by balance-sheet optionality and a plausible re-rating as management redeploys capital into fiber and tower leasing.
Bridgestone (BRDCY) has been hit by a risk-off move tied to recent geopolitical escalation that pushed cyclicals lower. Fundamentals remain intact: market cap ~$27.5B, P/E ~12.8, P/B ~1.15, dividend yield ~1.67% and active asset divestitures that should free cash. Technicals show oversold conditions (RSI ~31.6) and elevated short activity—condition…
Coca-Cola's brand moat and healthy cash generation make it an attractive defensive swing trade after a modest pullback; recent market flows that prize dividend resilience amplify the case, but high valuation, leverage and mixed technicals warrant a tight plan.
Xunlei (XNET) trades like a small-cap technology value stock despite recent strong headline earnings driven by investee gains. At roughly $394.7M market cap and a $6.28 share price, the risk/reward looks attractive for a mid-term swing trade if you size carefully and respect the stock's volatility.
AtaiBeckley (ATAI) is a clinical-stage psychedelics-focused biotech with Phase 3 momentum for BPL-003 (mebufotenin nasal spray) in treatment-resistant depression. With Phase 2a/2b data showing rapid, durable responses, FDA alignment, a planned Phase 3 start in Q2 2026, and $220.7M in runway into early 2029, I see an asymmetric risk/reward for a lon…
Kinross Gold (KGC) is trading below its short- and medium-term moving averages after a pullback, yet still commands a $34.7B market cap and reported record free cash flow in 2025. With a newly raised dividend and operational optionality across multiple jurisdictions, this is a tactical long trade: enter $29.00, stop $25.00, target $36.00 over a lon…
Carlisle (CSL) is a mature, cash-generative building-products play trading below its 50-day and 20-day averages after recent weakness. Strong free cash flow ($970.6M), a hefty ROE (41%), and an attractive EV/EBITDA (13.0) support a mid-term long. This trade idea proposes entry at $340.00, a stop at $312.00, and a target of $400.00 over a mid-term h…
Trip.com (TCOM) trades at a roughly $35.9B market cap with a P/E of 8.34 and PB of 1.52. The stock has been hit by a Chinese antitrust probe and related lawsuits, but core travel demand remains intact and technicals show the name near cyclical lows. This trade idea lays out an entry, stop and target for a long position with a 180-trading-day horizo…
Rocket Lab just moved from growth-only narrative to a vertically integrated space systems and defense play after a strategic acquisition and steady launch execution. Fundamentals and backlog support upside, but valuation is rich. This is a tactical mid-term long: entry $70.45, stop $60.00, target $95.00, horizon 45 trading days.
